What Does the Falsified Medicines Directive (FMD) Mean for SMEs and CMOs; and More Importantly, Are These Organisations Ready?

Jan 4, 2018

The implications of the directive are far-reaching and affect all pharmaceutical manufacturers, regardless of size. As time runs out and the deadline grows ever closer, Christian Taylor of Zetes explains in his article how CMOs and SME pharmaceutical manufacturers can ensure they are compliant. If smaller organisations embrace the regulatory changes – using them as an opportunity to optimise their supply chains, they can create true business value, making it pay to be compliant. ...

Read More